Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study)

(2019) Hiroaki Akamatsu et al.   LUNG CANCER

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS ‐mutant metastatic colorectal cancer

(2019) Elena Elez et al.   Molecular Oncology

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study

(2019) Maximilian J Hochmair et al.   Future Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis

(2019) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

(2019) Miguel-Angel Molina-Vila et al.   Journal of Thoracic Oncology

Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer

(2019) Eva Boysen Fynboe Ebert et al.   LUNG CANCER

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR -Mutant Lung Cancer

(2018) Chee Khoon Lee et al.   Journal of Thoracic Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

(2018) Ben O’Leary et al.   Nature Communications

Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR -mutated non-small cell lung cancer

(2018) Yunkyoung Lee et al.   Thoracic Cancer

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

(2017) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

(2017) Sheng-Kai Liang et al.   Oncotarget

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment

(2017) Mariano Provencio et al.   Oncotarget

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients

(2017) Mariano Provencio et al.   Oncotarget

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

(2017) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

(2016) Yi-Long Wu et al.   BRITISH JOURNAL OF CANCER

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY